Clinical trial
Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara…
NCT00079820 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00079820 |
|---|---|
| Title | Safety, Tolerability, and Immune Response of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine in Adults |
| Official title | The Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Modified Vaccinia Ankara (MVA) Smallpox Vaccine, in Adults Without Previous Smallpox Vaccination |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Smallpox |
| Intervention type | Biological |
| Interventions | ACAM3000 MVA Vaccine |
| Enrollment | 110 |
| Start date | Apr 1, 2004 |
| Primary completion | Oct 1, 2006 |
| Completion | Oct 1, 2006 |
| First posted | Mar 17, 2004 |
| Last update posted | Jan 13, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: